Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: Etoposide
Drug: Placebo

First Posted Date: 2014-11-13

Last Posted Date: 2020-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 221

Registration Number: NCT02289690

Locations: 🇨🇿
Vitkovicka nemocnice a. s. /ID# 149839, Ostrava, Czechia
🇰🇷
Chonnam National University Hwasun Hospital /ID# 153188, Jeonnam, Korea, Republic of
🇺🇸
Georgia Regents University /ID# 148567, Augusta, Georgia, United States

and more 59 locations

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Phase 3

Completed

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Veliparib
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2014-10-15

Last Posted Date: 2021-02-26

Lead Sponsor: AbbVie

Target Recruit Count: 595

Registration Number: NCT02264990

Locations: 🇨🇿
Multiscan s.r.o. /ID# 132689, Pardubice, Czechia
🇩🇪
Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany
🇹🇷
Inonu University /ID# 136569, Malatya, Turkey

and more 137 locations

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Veliparib Placebo
Drug: Veliparib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2014-06-16

Last Posted Date: 2024-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 509

Registration Number: NCT02163694

Locations: 🇺🇸
University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States
🇺🇸
Allegheny General Hospital /ID# 135094, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States

and more 216 locations

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Other: Quality-of-Life Assessment
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2014-06-02

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 447

Registration Number: NCT02152982

Locations: 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 393 locations

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: Placebo to veliparib
Drug: Paclitaxel

First Posted Date: 2014-04-08

Last Posted Date: 2020-11-17

Lead Sponsor: AbbVie

Target Recruit Count: 970

Registration Number: NCT02106546

Locations: 🇺🇸
Winship Cancer Institute of Emory University /ID# 124061, Atlanta, Georgia, United States
🇺🇸
Parkland Health and Hosp Syste /ID# 128518, Dallas, Texas, United States
🇺🇸
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 128385, Dallas, Texas, United States

and more 222 locations

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Colon Cancer
Solid Tumors
Breast Cancer
Ovarian Cancer
Gastric Cancer
Lung Cancer

Interventions: Drug: Veliparib
Drug: FOLFIRI
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2014-01-13

Last Posted Date: 2016-09-27

Lead Sponsor: AbbVie

Target Recruit Count: 47

Registration Number: NCT02033551

Locations: 🇪🇸
Site Reference ID/Investigator# 117451, Madrid, Spain
🇺🇸
Site Reference ID/Investigator# 117415, San Antonio, Texas, United States
🇳🇱
Site Reference ID/Investigator# 117338, Maastricht, Netherlands

and more 2 locations

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin
Drug: Veliparib

First Posted Date: 2014-01-10

Last Posted Date: 2021-01-20

Lead Sponsor: AbbVie

Target Recruit Count: 634

Registration Number: NCT02032277

Locations: 🇺🇸
Lehigh Valley Health Network /ID# 133372, Allentown, Pennsylvania, United States
🇺🇸
Texas Oncology - Medical City Dallas /ID# 126141, Dallas, Texas, United States
🇺🇸
UT Southwestern Medical Center /ID# 133849, Dallas, Texas, United States

and more 155 locations

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Veliparib
Drug: Gemcitabine
Radiation: Intensity modulated radiation therapy

First Posted Date: 2013-07-25

Last Posted Date: 2020-07-15

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 34

Registration Number: NCT01908478

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Phase 1

Completed

Conditions: BRCA Mutated
Oncology
BRCA Mutated Breast Cancer
High Grade Serous Ovarian Cancer

Interventions: Drug: Veliparib

First Posted Date: 2013-05-15

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 71

Registration Number: NCT01853306

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Drug: Temozolomide
Drug: Adavosertib
Drug: Everolimus
Drug: Trametinib
Drug: Veliparib
Drug: Carboplatin

First Posted Date: 2013-04-09

Last Posted Date: 2023-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 208

Registration Number: NCT01827384

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy